Dizal Announces Positive Pooled Data of Sunvozertinib in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Published in Lung Cancer
Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...
Hosted on MSN1d
AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC
AstraZeneca AZN and its Japanese partner Daiichi Sankyo announced that the FDA has granted a Breakthrough Therapy designation ...
Medscape10d
EGF Receptor Tyrosine Kinase Inhibitors in the Treatment of Brain Metastases From Non-small-cell Lung Cancer
EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs), given their low molecular weight, may be able to reach a higher concentration in brain tissues. Various reports and small studies ...
Pharmabiz1d
US FDA grants breakthrough therapy designation to datopotamab deruxtecan for patients with previously treated advanced EGFR-mutated NSCLC
US FDA grants breakthrough therapy designation to datopotamab deruxtecan for patients with previously treated advanced EGFR-mutated NSCLC: Cambridge, UK Tuesday, December 10, 2024 ...
MedPage Today20d
Treatment of Oligometastatic EGFR-Mutant Lung Cancer
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window EGFR tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR-mutant non-small cell lung cancer (NSCLC).
The Pharma Letter2d
First ‘Breakthrough’ designation for datopotamab deruxtecan
Datopotamab deruxtecan (Dato-DXd) has been granted Breakthrough Therapy designation (BTD) by the US Food and Drug ...
healthandpharma1d
FDA Grants Breakthrough Status to Datopotamab Deruxtecan for Advanced EGFR-Mutated Lung Cancer
The FDA has granted Breakthrough Therapy Designation to datopotamab deruxtecan (Dato-DXd) for advanced EGFR-mutated non-small cell lung cancer.
Targeted Oncology7d
FDA Grants Breakthrough Status to Sacituzumab Tirumotecan in EGFR+ NSCLC
The FDA granted breakthrough therapy status to sacituzumab tirumotecan in EGFR-mutated advanced non–small cell lung cancer.
AstraZeneca, Daiichi Sankyo announce BTD for datopotamab deruxtecan
Datopotamab deruxtecan has been granted Breakthrough Therapy Designation, or BTD, in the U.S. for the treatment of adult patients with locally ...
The American Journal of Managed Care1d
How to Choose Between Fixed-Duration vs Continuous BTKi Therapy for CLL
Sophia Humphreys, PharmD, MHA, BCBBS, a practicing pharmacist and health system director at Sutter Health, discussed the ...